
    
      it is a multicenter phase 2 ,double blind study in patient with active Rheumatoid arthritis
      ,there are 2 group in the study A and B ,where group A receive Rhustoxicodendron in 30
      potency the first dose will administered orally (1/2 ml)after the completion of case taking
      ,and repeated every 7th day for 5 month and on the other hand group B receive placebo orally
      in (1/2 ml) at same interval for same period .
    
  